|
|
||||||||
The Journal of Thoracic and Cardiovascular Surgery, Vol 82, 649-657, Copyright © 1981 by The American Association for Thoracic Surgery and The Western Thoracic Surgical Association
The Lung Cancer Study Group (LCSG) has tested the efficacy of intrapleural
bacillus Calmette-Guerin (BCG) as surgical adjuvant treatment in a
double-blind, randomized comparison against intrapleural saline. This
clinical trial included specific anatomic and pathological staging
requirements and careful follow-up monitoring. At this time, with a median
follow-up of 516 days in 216 treated and 209 control patients, no evidence
has yet been found that postoperative instillation of intrapleural BCG
improves survival or extends the disease-free interval in patients with
completely resected Stage I squamous cell carcinoma, adenocarcinoma, or
large cell carcinoma of the lung. There have been 93 recurrences and 77
deaths, which are remarkably evenly distributed in both arms of the study.
An unexpectedly superior survival rate for the Stage I group has been
observed, and the prognostic importance of cell type, TN status, and
elevations in initial white cell count and alkaline phosphatase measurement
has been confirmed.
ARTICLES
Surgical adjuvant intrapleural BCG treatment for stage I non-small cell lung cancer. Preliminary report of the National Cancer Institute Lung Cancer Study Group
This article has been cited by other articles:
![]() |
N. Martini, M. S. Bains, M. E. Burt, M. F. Zakowski, P. McCormack, V. W. Rusch, and R. J. Ginsberg Incidence of local recurrence and second primary tumors in resected stage I lung cancer J. Thorac. Cardiovasc. Surg., January 1, 1995; 109(1): 120 - 129. [Abstract] [Full Text] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |